There are currently 2876 clinical trials in Houston, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including M D Anderson Cancer Center, University of Texas MD Anderson Cancer Center, Baylor College of Medicine and The University of Texas - MD Anderson Cancer Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Causal Mechanisms in Adolescent Arterial Stiffness
NCT04128969
Recruiting
Hardening of the blood vessels, called arterial stiffness, is a risk factor for future heart disease and its causes are unclear. The proposed study will 1) randomly assign adolescents at high risk of stiffening blood vessels to take a protein supplement called carnitine and study its effects on arterial stiffening and 2) study carnitine related genes for their effect on arterial stiffening. The study will definitively establish a role for carnitine action as a cause of stiffening blood vessels a... Read More
Gender:
ALL
Ages:
Between 11 years and 21 years
Trial Updated:
05/02/2024
Locations: Texas Children's Hospital, Houston, Texas
Conditions: Lipid Disorder, Dyslipidemias, Aortic Stiffness, Insulin Resistance Syndrome, Metabolic Syndrome, Pediatric Obesity
Register for Updates
A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation
NCT06399393
Recruiting
The purpose of this study is to compare the efficacy, safety, and tolerability of ide-cel with lenalidomide (LEN) maintenance to that of LEN maintenance alone in adult participants with Newly Diagnosed Multiple Myeloma (NDMM) who have achieved a suboptimal response post autologous stem cell transplantation (ASCT).
Gender:
All
Ages:
18 years and above
Trial Updated:
05/01/2024
Locations: Houston Methodist Hospital, Houston, Texas +1 locations
Conditions: Multiple Myeloma
Register for Updates
Trial to Evaluate Safety, PD & PK of IV Study Drug, QN-302, in Pts w/ Advanced or Metastatic Solid Tumors
NCT06086522
Recruiting
Goal: learn about QN-302 in patients with solid tumors (metastatic, or advanced cancer). Main questions: * What does the study drug do to human body (Pharmacodynamics \[='PD'\]) * What does the body do to study drug (how processed in body (Pharmacokinetics \[='PK'\]) - Safety Study drug by intravenous infusion ('IV') once weekly for 3 weeks every 4-week 'cycle.' Study treatment continues as long as patient and their study doctor agree that study treatment is in the best interest of the patien... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/30/2024
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Solid Tumor
Register for Updates
A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies
NCT05753722
Recruiting
The goal of this Open-Label Study is to evaluate the safety and tolerability of PRTH-101 alone or in combination with pembrolizumab in adults with advance or metastatic solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2024
Locations: The University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Advanced or Metastatic Solid Tumors
Register for Updates
A Study of SNP-ACTH (1-39) Gel in Patients With Primary Membranous Nephropathy
NCT05696613
Recruiting
The goal of the Phase 3a part of this clinical trial is to determine the optimal dose that will be used in the Phase 3b part of this clinical trial. The goal of the Phase 3b part is to assess the efficacy of SNP-ACTH (1-39) Gel relative to rituximab in patients with primary membranous nephropathy (PMN) at month 24.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/24/2024
Locations: Prolato Clinical Research Center, Houston, Texas
Conditions: Primary Membranous Nephropathy
Register for Updates
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
NCT04771572
Recruiting
This is a Phase 1, multi-center, open-label study with a dose-escalation phase (Phase 1a) and a cohort expansion phase (Phase 1b), to evaluate the safety, tolerability, and PK profile of LP-118 under a once daily oral dosing schedule in up to 100 subjects.
Gender:
ALL
Ages:
13 years and above
Trial Updated:
04/23/2024
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Non Hodgkin Lymphoma, Richter Transformation, Multiple Myeloma, T-cell-prolymphocytic Leukemia, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Myeodysplastic Syndrome, Myelofibrosis, Myelodysplastic/Myeloproliferative Neoplasm, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Chronic Myelomonocytic Leukemia-2, Myelodysplastic Neoplasm in Blast Phase
Register for Updates
A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors
NCT05989724
Recruiting
This proposed Phase I clinical trial of SON-DP is an FIH, open-label, Phase Ia/Ib dose escalation and expansion study to evaluate the safety, tolerability, PK, and PD of SON-DP in participants with relapsed/refractory/intolerant to standard of care therapies, for advanced/ metastatic solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/23/2024
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Solid Tumor, Breast Cancer, Pancreatic Cancer, Ovarian Cancer, Colorectal Cancer
Register for Updates
Systemic and Central Inflammation in AD
NCT06384378
Recruiting
Inflammation could provide a new focus for therapeutic intervention. In this study, we will measure blood and cerebrospinal fluid (CSF) inflammation biomarkers and compare them to measurements of brain glial activation obtained by positron emission tomography (PET). In addition, we will determine the effect of low-dose interleukin-2 (IL-2) immunotherapy, given over 22 weeks, on these inflammation biomarkers.
Gender:
ALL
Ages:
Between 50 years and 86 years
Trial Updated:
04/22/2024
Locations: Houston Methodist Research Institute, Houston, Texas
Conditions: Alzheimer Disease
Register for Updates
A Prospective Study of Conventional Bone Marrow Biopsy Versus Portomar(TM) Biopsy
NCT05583734
Recruiting
This is a self-controlled, prospective trial. The objective of this trial is to evaluate the efficacy and safety of the Portomar(TM) device for bone marrow biopsy.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
04/21/2024
Locations: MD Anderson, Houston, Texas
Conditions: Hematologic Malignancy
Register for Updates
Accessing Mobility Using Wearable Sensors
NCT04306588
Recruiting
This study will examine whether wearable sensors can be used to track changes in cognitive-motor performance in response to a disease or an intervention. The investigators specific aims are twofold, first aim to explore whether and how a clinical condition such as Chronic obstructive pulmonary disease (COPD) or Congestive Heart Failure (CHF) may impact motor-cognitive performance measurable using validated wearable devices (e.g., LEGSys, BalanSENS, and Frailty Meter). Second, the investigators... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/19/2024
Locations: Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas
Conditions: COPD, Pulmonary Disease, Pulmonary Restrictive Disease, Congestive Heart Failure, Cardiovascular Diseases
Register for Updates
The Effect of Fluids on Aortic VTI During C-section
NCT04330742
Recruiting
Pregnancy is associated with a myriad of physiologic changes, including expansion of blood volume, decrease in oncotic pressure, and increased cardiac output. The obstetric population is associated with intrapartum hemorrhage. Accordingly, it is important to have an accurate method to assess fluid status in intrapartum patients. The use of standard volume assessment tools including arterial lines and central venous catheters is limited given the brevity of obstetric procedures and the morbidity... Read More
Gender:
FEMALE
Ages:
Between 18 years and 35 years
Trial Updated:
04/19/2024
Locations: Ben Taub General Hospital, Houston, Texas
Conditions: Pregnancy Related, Hemorrhage, Fluid Overload, Labor Complication
Register for Updates
Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2
NCT05555589
Recruiting
The objective of this study is to compare the safety and efficacy of RGN-259 to placebo for the treatment of Neurotrophic Keratopathy (NK)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/17/2024
Locations: Houston Eye Associates, Houston, Texas
Conditions: Neurotrophic Keratopathy
Register for Updates